Consequences of intermittent calcitriol therapy in pediatric patients with secondary hyperparathyroidism

Peritoneal Dialysis International

Volumn 19, Issue SUPPL. 2, 1999, Pages

  Salusky, Isidro B ^a,b   Goodman, William G ^a   Kuizon, Beatriz D ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UCLA MEDICAL CENTER   (United States)

Author keywords

Bone disease; Children; Dialysis; Growth; Vitamin D therapy

Indexed keywords

CALCITRIOL; CALCIUM; CALCIUM CARBONATE; PHOSPHORUS;

ADOLESCENT; CALCIUM BLOOD LEVEL; CLINICAL ARTICLE; CONFERENCE PAPER; CONTROLLED STUDY; GROWTH RETARDATION; HUMAN; KIDNEY FAILURE; PERITONEAL DIALYSIS; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; SCHOOL CHILD; SECONDARY HYPERPARATHYROIDISM;

EID: 0033396558     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: 10.1177/089686089901902s72     Document Type: Conference Paper

References (14)

1. Salusky IB, Coburn JW, Brill J, Foley J, Slatopolsky E, Fine RN, et al. Bone disease in pediatric patients undergoing dialysis with CAPD or CCPD. Kidney Int. 1988; 33:975-82.
2. Sherrard DJ, Hercz G, Pei Y, Maloney N, Greenwood C, Manuel A, et al. The spectrum of bone disease in end-stage renal failure - An evolving disorder. Kidney Int. 1993; 43:436-42.
3. Rodriguez-Perez JC, Plaza C, Torres A, Vega N, Anabitarte A, Fernandez A, et al. Low turnover bone disease is the more common form of bone disease in CAPD patients. In: Khanna R, Nolph KD, Prowant BF, Twardowski ZJ, Oreopoulos DG, eds. Advances in Peritoneal Dialysis. Toronto: Peritoneal Dialysis Bulletin, 1992; 8:376-80.
4. Goodman WG, Salusky IB. Evolution of secondary hyperparathyroidism during daily oral calcitriol therapy in pediatric renal osteodystrophy. Contrib Nephrol. 1991; 90:189-95.
5. Goodman WG, Ramirez JA, Belin TR, Chon Y, Gales B, Segre GV, et al. Development of adynamic bone in patients with secondary hyperparathyroidism after intermittent calcitriol therapy. Kidney Int. 1994; 46:1160-6.
6. Slatopolsky E, Weerts C, Thielan J, Horst RL, Harter H, Martin KJ. Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxycholecalciferol in uremic patients. J Clin Invest. 1984; 74:2136-43.
7. Quarles LD, Yohay DA, Carroll BA, Spritzer CE, Minda SA, Bartholomay D, et al. Prospective trial of pulse oral versus intravenous calcitriol treatment of hyperparathyroidism in ESRD. Kidney Int. 1994; 45:1710-21.
8. Salusky IB, Kuizon BD, Belin TR, Ramirez JA, Gales B, Segre GV, et al. Intermittent calcitriol therapy in secondary hyperparathyroidism: A comparison between oral and intraperitoneal administration. Kidney Int. 1998; 54:907-14.
9. Salusky IB, Fine RN, Nelson P, Blumenkrantz MJ, Kopple JD. Nutritional status of children undergoing continuous ambulatory peritoneal dialysis. Am J Clin Nutr. 1983; 38:599-611.
10. Salusky IB, Adams JS, Horst R, Holloway M, Coburn JW, Goodman WG, et al. Enhanced calcitriol delivery after intraperitoneal administration [Abstract]. Kidney Int. 1989; 35:244.
11. Delmez JA, Dougan CS, Gearing BK, Rothstein M, Windus DW, Rapp N, et al. The effects of intraperitoneal calcitriol on calcium and parathyroid hormone. Kidney Int. 1987; 31:795-9.
12. Kuizon BD, Goodman WG, Jüppner H, Boechat I, Nelson P, Gales B, et al. Diminished linear growth during intermittent calcitriol therapy in children undergoing CCPD. Kidney Int. 1998; 53:205-11.
13. Andress DL, Norris KC, Coburn JW, Slatopolsky EA, Sherrard DJ. Intravenous calcitriol in the treatment of refractory osteitis fibrosa of chronic renal failure. N Engl J Med. 1989; 321:274-9.
14. Berger N, Mehls O, Schmitt CP, Oh J. Daily calcitriol but not pulse therapy improves growth in experimental uremia [Abstract]. J Am Soc Nephrol. 1996; 7:1787.